NAD+, NMN, and NR:
The Aging Currency Your Cells Run On

What Is NAD+ and Why Does Every Cell Depend on It?

Nicotinamide adenine dinucleotide (NAD+) is not a vitamin, a hormone, or a single-pathway enzyme. It is a coenzyme — a molecular workhorse that participates in hundreds of biochemical reactions and is present in every living cell in your body. Without adequate NAD+, cellular energy production collapses, your genome becomes increasingly unstable, and the molecular machinery of healthy aging breaks down.

Energy Metabolism — The Electron Carrier Role

In its reduced form (NADH), NAD+ shuttles electrons through the core energy-producing pathways of cellular metabolism. During glycolysis, NAD+ accepts electrons from glucose breakdown. In the TCA (tricarboxylic acid) cycle, it captures high-energy electrons from acetyl-CoA oxidation. Those electrons are then handed off to Complex I of the mitochondrial electron transport chain, where they drive the proton gradient that synthesizes ATP — the universal energy currency of the cell.

This is not a niche function. Every time you breathe and every ATP molecule your muscles produce depends on NAD+ cycling between its oxidized (NAD+) and reduced (NADH) forms. A meaningful deficit in NAD+ availability translates directly into mitochondrial dysfunction and reduced cellular energy output.

DNA Repair — The PARP Connection

PARP (poly ADP-ribose polymerase) enzymes are your genome's first-responders. When DNA damage occurs — from UV radiation, oxidative stress, or replication errors — PARP enzymes detect the break and recruit repair machinery to the site. They do this by consuming NAD+ at a remarkable rate, using it to synthesize ADP-ribose chains that signal the repair cascade.

The problem is scale: with aging comes an accumulating burden of DNA damage, driving PARP activity chronically upward and consuming NAD+ faster than aging cells can synthesize it. This creates a vicious cycle — more DNA damage demands more PARP, more PARP depletes more NAD+, and less NAD+ means less sirtuin activity to maintain genome stability in the first place.

The NAD+ Decline: Why It's Causal, Not Just Correlative

The roughly 50% decline in cellular NAD+ levels from young adulthood to old age is one of the most reproduced findings in aging biology. But correlation does not equal causation — and the field has moved well beyond that distinction.

Three Mechanisms Drive the Decline

1. CD38 upregulation. CD38 is an NAD+ase — an enzyme that degrades NAD+ and its precursors. As chronic low-grade inflammation increases with age (a phenomenon sometimes called "inflammaging"), CD38 expression rises sharply. Studies have shown that aged mice have substantially higher CD38 activity in liver and fat tissue, directly accounting for much of their NAD+ depletion. Pharmacological inhibition of CD38 in aged mice raises NAD+ and improves metabolic function — a direct mechanistic link.

2. Increased PARP activity. As described above, the accumulating DNA damage burden of aging drives PARP enzymes to chronically consume NAD+. This is not a transient spike but a sustained drain that outpaces the cell's replenishment capacity.

3. Decreased biosynthesis. The primary NAD+ biosynthesis pathway from tryptophan (the de novo pathway via kynurenine) and the salvage pathway from nicotinamide both show reduced efficiency with age. Key enzymes including NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway, decline in expression in aged tissues.

Causality: What Animal Models Tell Us

The causal case comes from intervention experiments. In multiple mouse studies, restoring NAD+ via precursor supplementation or genetic manipulation of biosynthetic enzymes reverses multiple aging phenotypes: improved mitochondrial function, enhanced muscle endurance, better insulin sensitivity, reduced neurodegeneration markers, and extended lifespan in some model organisms. These are not associations — they are mechanistic interventions that produce measurable biological reversal.

This does not automatically translate to identical effects in humans, but it shifts the question from "is NAD+ relevant?" to "how much can we restore, and does restoration produce clinically meaningful benefits?"

Sirtuins: Your NAD+-Gated Longevity Enzymes

Sirtuins are a family of seven NAD+-dependent deacetylase and ADP-ribosyltransferase enzymes (SIRT1 through SIRT7) that regulate an extraordinary range of cellular processes. They are not merely longevity-associated proteins — they are mechanistically central to how cells respond to metabolic stress, repair DNA damage, and maintain epigenetic stability.

The critical feature of sirtuins from a NAD+ perspective is this: they require NAD+ as a co-substrate to perform their enzymatic function. They do not merely bind NAD+ for structural reasons — they consume it, splitting off nicotinamide as a reaction byproduct. This means sirtuin activity is directly gated by NAD+ availability. When NAD+ is low, sirtuins are underactive regardless of their expression levels.

SIRT1 — Gene Expression and DNA Repair

SIRT1 is the most studied sirtuin. It deacetylates histones and transcription factors to regulate gene expression, activates FOXO transcription factors that govern stress resistance and apoptosis, and participates directly in DNA damage repair by recruiting repair factors to double-strand breaks. SIRT1 also regulates PGC-1α — the master regulator of mitochondrial biogenesis. When NAD+ is adequate, SIRT1 activation drives cells toward a repair-and-maintain mode. When NAD+ is depleted, this protective program weakens.

SIRT3 — Mitochondrial Homeostasis

SIRT3 resides in the mitochondrial matrix and deacetylates the key enzymes of oxidative phosphorylation, the TCA cycle, and antioxidant defense. It activates superoxide dismutase 2 (SOD2), the primary mitochondrial antioxidant enzyme, by deacetylation. Mice lacking SIRT3 show accelerated mitochondrial dysfunction and increased oxidative stress — essentially a premature aging phenotype at the mitochondrial level. Adequate NAD+ keeps SIRT3 active and mitochondria healthy.

SIRT6 — Genome Stability and Longevity

SIRT6 has perhaps the strongest direct link to longevity. It deacetylates histones at DNA double-strand breaks, facilitating repair. Mice overexpressing SIRT6 live significantly longer than wild-type controls. Mice lacking SIRT6 display a dramatic accelerated aging syndrome and die young. SIRT6 also suppresses LINE-1 retrotransposon activity — the jumping genetic elements that become increasingly active with aging and drive genomic instability. All of this activity requires NAD+.

NMN vs NR vs Niacin: The Biosynthesis Map

NAD+ cannot be taken as a supplement directly — it is too large and charged to cross cell membranes efficiently. Instead, the field has focused on precursors: smaller molecules that cells can absorb and convert to NAD+ through established enzymatic pathways. Understanding which precursor enters the pathway where determines how they compare.

NMN (Nicotinamide Mononucleotide)

NMN sits one step upstream of NAD+ in the biosynthesis pathway, requiring only the NMNAT enzyme family to complete conversion. For years it was assumed that NMN must be first dephosphorylated to NR before crossing the intestinal wall (since a specific NMN transporter was unknown in humans). A 2019 paper identified Slc12a8 as an NMN transporter in mice intestinal cells — but whether a human equivalent operates similarly remains under investigation. What is not in dispute is that oral NMN supplementation reliably raises NAD+ levels in human blood and tissues.

The landmark human trial was Yoshino et al. (2021, Science) — the first placebo-controlled RCT of NMN in humans. Twenty-five premenopausal and postmenopausal women with prediabetes or overweight received 250mg/day NMN or placebo for 10 weeks. Results: significantly improved skeletal muscle insulin signaling, increased NMN uptake into muscle, and activation of SIRT1 target genes in muscle tissue. This was a small trial with a specific population, but it was the first human RCT to show tissue-level mechanistic effects beyond just blood NAD+ elevation.

Sublingual NMN: Okabe et al. (2022) compared sublingual vs oral capsule NMN administration and found sublingual delivery produced significantly faster absorption and higher peak blood NMN and NAD+ levels. This suggests sublingual formulations may be superior for acute NAD+ elevation, bypassing first-pass intestinal and hepatic metabolism.

NR (Nicotinamide Riboside)

NR was identified as a novel NAD+ precursor by Charles Brenner (then at Dartmouth, now Iowa), who also identified the NRK1/2 kinase pathway it uses for conversion to NMN. This discovery was published in 2004 in Cell and established NR as a distinct entry point into the NAD+ biosynthesis pathway.

NR has the most extensive human trial evidence of any NAD+ precursor for raising blood NAD+ levels. Elhassan et al. (2019) showed that 300mg NR over 6 weeks significantly elevated whole blood NAD+ in healthy middle-aged adults. ChromaDex (the primary NR manufacturer, which sells it as Tru Niagen) has funded multiple human trials consistently showing blood NAD+ elevation. The limitations are that most NR trials have focused on blood NAD+ as the primary endpoint rather than functional or clinical outcomes.

The NMN vs NR debate — represented in academic terms by David Sinclair championing NMN and Charles Brenner championing NR — is real and ongoing. Without a published head-to-head human RCT, the scientific literature cannot definitively declare a winner. Both elevate blood NAD+. NMN has one notable tissue-specific functional RCT; NR has more total human trial volume.

Niacin and Nicotinamide

Niacin (nicotinic acid, NA) enters NAD+ biosynthesis via the Preiss-Handler pathway — a distinct route from NMN/NR. It is one of the most potent NAD+ precursors available, highly effective at raising NAD+ in liver, and inexpensive. The major limitation is the prostaglandin-mediated skin flush at pharmacological doses (typically starting above 50mg), which many users find intolerable.

Nicotinamide (NAM) enters via the salvage pathway — the same route as NMN and NR ultimately converge on. It is NAD+-efficient and does not cause flushing. However, nicotinamide is also the byproduct of sirtuin reactions and acts as a feedback inhibitor of SIRT1 and other sirtuins at elevated concentrations. This creates a meaningful theoretical tension: supplementing nicotinamide raises NAD+ but may simultaneously blunt sirtuin activity, potentially defeating part of the purpose of NAD+ restoration for longevity purposes.

NMN vs NR vs Niacin: Side-by-Side Comparison

What the Human Evidence Actually Shows

It is important to distinguish between what is established and what remains speculative when evaluating NAD+ precursor supplementation in humans. The animal data is compelling — in mice, NMN and NR supplementation reverses multiple aging phenotypes in ways that are clearly causal. The human data is younger, smaller in scale, and more modest in scope.

Yoshino 2021: The NMN Landmark

This was the first placebo-controlled, double-blind RCT of NMN in humans, published in Science. The design: 25 overweight or obese postmenopausal women with prediabetes, randomized to 250mg/day oral NMN or placebo for 10 weeks. The primary findings were compelling in their specificity: NMN significantly improved skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp), increased expression of genes regulated by SIRT1 in muscle, and demonstrated that orally consumed NMN was taken up directly into skeletal muscle — answering the earlier mechanistic question about tissue penetration in humans.

The limitations are real: small sample size, specific population (postmenopausal women with prediabetes), and a 10-week duration. But this trial shifted NMN from "plausible animal model intervention" to "demonstrated tissue-level mechanistic effects in humans."

NR Trials: Robust Biomarker Data

The NR evidence base for blood NAD+ elevation is the most extensive among all precursors in the human literature. Elhassan et al. (2019) showed that 300mg NR per day for 6 weeks significantly elevated whole blood NAD+ in healthy middle-aged adults without meaningful adverse effects. Multiple ChromaDex-funded trials have replicated the blood NAD+ elevation finding across different populations and dose levels — the consistency here is notable even accounting for funding source.

The gap in NR trials is clinical functional outcomes. Most trials measured blood NAD+ as their primary endpoint, not muscle function, metabolic parameters, or other functional markers. This is not evidence of inefficacy — it reflects where the science is, not where it ends.

The Head-to-Head Gap

As of mid-2026, no published RCT has directly compared NMN vs NR in the same human population with the same endpoints. This is the most significant gap in the field. Both elevate blood NAD+; whether one elevates it more in specific tissues, at lower doses, or with greater functional impact is genuinely unknown from controlled human data. Researchers including Charles Brenner have argued that the conversion pathway question (whether NMN must convert to NR before cell entry) makes NR mechanistically simpler and potentially more efficient. David Sinclair has countered that the Slc12a8 transporter data and tissue-specific effects favor NMN. The honest answer is: watch for the head-to-head trial data.

Recommended: Verified NAD+ Precursors

As an Amazon Associate we earn from qualifying purchases. We only recommend products with evidence-aligned dosing. Always consult a healthcare provider before starting new supplements.

Frequently Asked Questions

Continue Reading